Detection of human parvovirus 4 viremia in the follow-up blood samples from seropositive individuals suggests the existence of persistent viral replication or reactivation of latent viral infection

Mao-Yuan Chen*, Chien-Ching Hung and Kuang-Lun Lee

Abstract

**Background:** The transmission routes for human parvovirus 4 (PARV4) infections in areas with high seroprevalence are not known. In the work described here, persistent PARV4 viral replication was investigated by conducting a longitudinal study.

**Methods:** Ten healthcare workers each provided a blood sample at the beginning of the study (first sample) and 12 months later (second sample). The paired samples were tested for PARV4-positivity by immunoblotting analysis and nested polymerase chain reactions.

**Results:** IgG antibodies against PARV4 were detected in six participants, three of whom also had IgM antibodies against PARV4. The immunoblotting results did not vary over time. PARV4 DNA was detected in the first blood sample from one participant who had IgG antibodies against PARV4 and in the second blood samples from 2 participants who had IgG and IgM antibodies against PARV4.

**Conclusions:** Detection of PARV4 DNA in the second blood samples from two seropositive participants suggests the existence of persistent PARV4 replication or reactivation of inactive virus in the tissues. The finding of persistent or intermittent PARV4 replication in individuals with past infections provides an important clue toward unraveling the non-parenteral transmission routes of PARV4 infection in areas where the virus is endemic.

**Keywords:** Parvovirus 4, Persistent PARV4 infection, Latent PARV4 infection, Anti-PARV4 IgM

Background

In the subfamily Parvovirinae of the family Parvoviridae, members of four genera are currently known to infect humans, namely parvovirus B19 (B19V, genus Erythroparvovirus), human bocavirus (genus Bocaparvovirus), adeno-associated viruses (genus Dependoparvovirus) and human parvovirus 4 (PARV4, genus Tetraparvovirus); of these, the former two viruses can cause human diseases [1]. PARV4 was discovered in an intravenous drug user with an acute viral infection syndrome [2]. However to date, the clinical manifestations of PARV4 infection remain largely unknown. The seroprevalence of PARV4 varies geographically, but antibodies against PARV4 have been detected in 24.8 % of the general population in Cameroon in contrast to none of the general population in the United Kingdom [3]. Early serological studies supported a predominantly parenteral route for PARV4 infection in northern Europe because the seropositivity rates were 0 % and 0.9 % in the study groups where a risk of parenteral infection was not found [4, 5]. By contrast, recent studies found that 9.4 % of a low-risk group in Lithuania and 4.76 % of United Kingdom blood donors tested positive for PARV4 antibodies [6, 7]. How the study subjects in these two reports [6, 7] acquired PARV4 infection is not known.
The strong immune response induced by acute B19V infection can eliminate B19V viremia. Persistent B19V viremia does exist [8] but is infrequently found and characterized by a low viral load. However, B19V DNA frequently remains detectable in tissues long after viral exposure, perhaps even after a lifetime [9]. Similarly, PARV4 viremia was estimated to last only between 32 and 104 days in study subjects who displayed seroconversion [10] and PARV4 DNA could also be detected in 15 to 41 % of the liver, myocardium, lung and kidney tissues from non HIV-infected individuals in the absence of viremia which suggests persistence of viral DNA in tissues [11, 12]. Not every study found PARV4 DNA in tissue samples from non HIV-infected study subjects [13], although B19V and PARV4 DNA were detected in 54 % and 71 % of autopsy tissue samples, respectively, from HIV-infected study subjects in the same study [13]. However, both B19V and PARV4 DNA were absent in the plasma of 36 previously untreated HIV-infected patients despite the high probability of viral DNA persistence in tissue samples [13]. These findings raise the question of whether these viruses in tissues have the ability to actively replicate. In addition, the detection rate of B19V DNA in plasma was low (0.9 %) in blood donors from the United Kingdom despite 60.5 % of them being positive for anti-B19V IgG [14]. This suggests that most of the blood donors with past B19V infections do not have active B19V replication in their tissues or have replication levels below detection limit. In the case of PARV4, it was reported that the PARV4 DNA detection rate in blood donors from Los Angeles (USA) was low (2 %); however, the PARV4 seropositive rate is not known [15]. Although no direct evidence to date has supported persistent PARV4 replication in the host, the observation of sustained T cell responses against PARV4 without viremia suggests PARV4 may persist at levels below detection limit [10, 16].

In our previous report, the seven sequential blood sample collections from one HIV-infected male over a period of 21 months all tested positive for anti-PARV4 IgM but PARV4 DNA was found only in the second blood sample [17]. The patient might have had persistent PARV4 viremia, but the viral load was below the detection limit of the test method as has been reported previously in cases of persistent B19V viremia [8]. However, the possibility of re-infection could not be excluded because this was an immune-compromised host. To investigate the existence of PARV4 replication in healthy individuals with past PARV4 infections, we conducted the present study.

Methods

Study group

In this longitudinal study, ten healthcare workers (nine females) in our AIDS Center (National Taiwan University Hospital, Taiwan) donated blood on two occasions, with each donation 12 months apart. Their ages at the time of the first donation are listed in the Table. For each participant, 5 ml of blood was collected in an EDTA tube and the plasma was stored at −30 °C. The PARV4 serological status of these participants was unknown to us when they enrolled in the study. The investigation was carried out in accordance with the principles of the Declaration of Helsinki, and all of the participants provided informed consent. The collections of blood samples were approved by the ethics committee of the National Taiwan University Hospital.

Immunoblotting and nested polymerase chain reaction (PCR)

Antibodies against PARV4 were detected using an immunoblotting method developed by our group [17]. Two of the recombinant fusion proteins used, SUMOV2 (amino acids 272–630 of the translated PARV4 open reading frame, ORF2) and SUMOV3 (amino acids 604–914 of the translated ORF2), and the control protein have been described in our previous study [17]. Here, an additional fusion protein SUMOV1 (amino acids 1–275 of the translated ORF2) was generated by the methods used in our previous report [17]. The immunoblotting assays were analyzed by two independent researchers (blinded), and samples with reactivity to fusion protein VP1, VP2, or VP3 were considered seropositive.

PARV4 DNA was detected using nested PCR. Viral DNA was extracted from 200 μL of plasma, using the High Pure Viral Nucleic Acid Kit (Roche, Mannheim Germany). The elution volume was 50 μL, and 5 μL was used in each reaction. The PARV4 primers (designated to detect PARV4 genotype 2) have the following sequences: forward: 5’-ATTTCTGTAGCTCCACCAGGAGC-3’ (nucleotide, nt.3 to 267), and inner primer: 5’-CCATAAACCTC TAATAGCATTGCC-3’ (nt.903 to 880), inner forward: 5’-CGGGATCAGCTCCTTCTCATCG CG-3’ (nt.610 to 589). The thermo-cycling conditions for nested PARV4 PCR in the first and second rounds were 94 °C for 2 min, followed by 36 cycles of 94 °C for 30 s, 54 °C for 30 s, and 72 °C for 30 s with a final extension of 7 min at 72 °C. PCR products were validated by sequencing and each DNA sample was tested using nested PCR six times, with the PARV4 ORF1 DNA template being included in each of 12 PCR experiments in this study as a negative control. The PCR experiments were repeated because it has been shown that PCR replicates are required to identify persistent B19V viremia when the B19V viral load is lower than the detection limit [8]. When six PCR replicates were performed on DNA samples with concentrations of 1, 0.5 or 0.25 PARV4...
plasmid copies/μL, the number of positive results amounted to 6, 2 or 0, respectively.

Results and discussion

The serological and PCR results from the longitudinal study are listed in Table 1. Notably, the immunoblotting results for the 10 study participants in this study did not change over time. Anti-PARV4 IgM persisted without weakening in all three of the IgM-positive participants and IgG reactivity also remained constant (participant 9 and 10 are shown in Figs. 1 and 2, respectively). The IgG reactivity of participant 9 was so weak that it could hardly be detected after scanning (Fig. 2). One blood sample collected from participant 9 at 32 months before the start of the study also had the same immunoblotting results (strip not shown). We cannot explain the persistence of IgM reactivity with weak IgG reactivity noted in participants 9 and 10 (both were PARV4 DNA-positive) but this pattern is not uncommon in our experience and these subjects were likely to be diagnosed as having current PARV4 infection without knowledge of their preceding immunoblotting results. Interestingly, the PARV4 DNA-positive participant (number 7) who was negative for anti-PARV4 IgM also had weak IgG reactivity (Fig. 2). PARV4 DNA was detected only in the first sample (one participant) or in the second sample (two participants). The number of positive PCR replicates was one (two samples) or 2 (one sample). The three nucleotide sequences of the PCR products are identical to the corresponding region of the GenBank sequence GU120197.1.

Both B19V and PARV4 viruses have two capsid proteins, VP1 and VP2 [18], and antibodies against linear B19V VP2 epitopes have been shown to disappear 6 months after acute B19V infection [19]. In the present study, the three PARV4-SUMO fusion proteins SUMOVP1 (aa. 1–275 of the translated PARV4 open reading frame, ORF2), VP2 represents SUMOVP2 (aa. 272–630 of translated ORF2) and VP3 represents SUMOVP3 (aa. 604–914 of translated ORF2). The molecular weight markers (kDa) are 170, 130, 100, 70, 55, 40, 35 and 25 from top to bottom of each blot. G: IgG; M: IgM; aa.: amino acid

| Participant | Sex | Age | Sample | Anti-PARV4 immunoglobulin | No. of positive results in six PCR replicates |
|-------------|-----|-----|--------|--------------------------|---------------------------------------------|
| 1           | M   | 38  | 1      | Negative                 | 0/6                                         |
|             |     |     | 2      | Negative                 | 0/6                                         |
| 2           | F   | 45  | 1      | Negative                 | 0/6                                         |
|             |     |     | 2      | Negative                 | 0/6                                         |
| 3           | F   | 24  | 1      | Negative                 | 0/6                                         |
|             |     |     | 2      | Negative                 | 0/6                                         |
| 4           | F   | 36  | 1      | Negative                 | 0/6                                         |
|             |     |     | 2      | Negative                 | 0/6                                         |
| 5           | F   | 26  | 1      | IgG positive              | 0/6                                         |
|             |     |     | 2      | IgG positive              | 0/6                                         |
| 6           | F   | 32  | 1      | IgG positive              | 0/6                                         |
|             |     |     | 2      | IgG positive              | 0/6                                         |
| 7           | F   | 28  | 1      | IgG weakly positive       | 1/6                                         |
|             |     |     | 2      | IgG weakly positive       | 0/6                                         |
| 8           | F   | 25  | 1      | IgG & IgM positive        | 0/6                                         |
|             |     |     | 2      | IgG & IgM positive        | 0/6                                         |
| 9           | F   | 30  | 1      | IgG weakly positive & IgM positive | 0/6                                      |
|             |     |     | 2      | IgG weakly positive & IgM positive | 2/6                                      |
| 10          | F   | 24  | 1      | IgG & IgM positive        | 0/6                                         |
|             |     |     | 2      | IgG & IgM positive        | 1/6                                         |

M male, F female, No. number

Fig. 1 PARV4 immunoblots from study participant No. 10. The two blood samples collected from this subject 12 months apart are represented by 1 and 2. PARV4 DNA was detected in the second but not the first blood sample. Note the strong IgM and weak IgG reactivity over the study period. VP1 represents the fusion protein SUMOVP1 (aa. 1–275 of the translated PARV4 open reading frame, ORF2); VP2 represents SUMOVP2 (aa. 272–630 of translated ORF2) and VP3 represents SUMOVP3 (aa. 604–914 of translated ORF2). The molecular weight markers (kDa) are 170, 130, 100, 70, 55, 40, 35 and 25 from top to bottom of each blot. G: IgG; M: IgM; aa.: amino acid
seroconversion; the anti-PARV4 IgM became undetectable in the blood sample collected after a month [10]. For the one exception, two sequential blood samples tested positive for anti-PARV4 IgM, and the duration of the IgM response was 32–93 days. All the IgM-positive blood samples collected at seroconversion had detectable PARV4 DNA, but viremia disappeared in the second IgM-positive blood sample collected after one month and the duration of viremia was estimated to have lasted between 32 and 98 days. This result suggested that anti-PARV4 IgM and PARV4 viremia were both short-lived and the existence of PARV4 DNA was expected in most of the IgM-positive blood samples. In contrast, a serological study conducted in Finland found that four (5.1 %) HIV-infected intravenous drug users tested positive for anti-PARV4 IgM and PARV4 viremia [5]. Furthermore, the presence of high-avidity anti-PARV4 IgG indicated that the four drug users had previous immunity rather than primary infection. Additionally, the anti-PARV4 IgM-positive rate was 7 % in a Lithuanian study on patients with acute respiratory disease in contrast to 0.9 % in a Finnish study on university students [5, 6]. These IgM-positive Lithuanian patients were grouped into current (IgM+, IgG−) ongoing, or recent PARV4 infection groups (IgM+, IgG+); however, PARV4 DNA was not detectable in any of the IgM-positive blood samples. In our experience, IgM antibodies against PARV4 can remain detectable for 12 months or longer, and the high IgM-positive rates are explainable by a prolonged IgM response, but PARV4 DNA might not have been detected in IgM-positive blood samples without conducting PCR replicates.

In the present study, the possibility of low-level viral infections in some subjects is suggested by the infrequent positive results of the PCR replicates, but false positive results seem unlikely because not a single negative control was positive (a total of 12 negative control reactions were performed in this study). Furthermore, the PARV4 DNA-positive blood samples in our PARV4 studies to date have always shown PARV4 antibody positivity with only one exception; this uneven distribution conflicts with the false positive results. A low viral load in the presence of anti-PARV4 IgG without IgM was noted in one participant (number 7 in the table), this was considered to result from persistent viral replication in a B19V study of blood donors [14]. Our study does not demonstrate persistent viral replication directly because PARV4 viremia was not found at more than one time point. Nevertheless, the detection of PARV4 DNA in the second of the two blood samples from two participants who were positive for anti-PARV4 IgM and IgG strongly suggests the existence of persistent PARV4 replication for the following reasons. (1) Primary PARV4 infection can be excluded because of the pre-existing anti-PARV4 IgM and IgG, which suggests the possibility of persistent PARV4 replication, reactivation of latent PARV4 infection or re-infection. (2) Re-infection can boost the pre-existing IgG antibody response, but this was not observed in the two study participants. (3) The low (1/35) seropositive rate in siblings of PARV4-infected hemophiliac patients [4] and the low PARV4 seroprevalence in United Kingdom blood donors [7] suggest that PARV4 is not easily transmitted by person-to-person contact through non-parenteral routes hence the chance of re-infection is low. (4) It is possible that persistent low-level viral replication below the detection limit existed in the first blood samples, but reappearance of viremia due to reactivation of inactive virus in the tissues is also possible.

Conclusions

The three PARV4 DNA-positive participants in this study were females of child-bearing age and persistent PARV4 replication is a possibility for them. If they become pregnant, PARV4 virus may be transmitted to their newborns, as was shown in our previous study [20]. Trans-placental PARV4 infection may be one of the major transmission routes in Taiwan because PARV4 seroprevalence in healthcare workers is high (43.6 %) [17], and 26 % of the seropositive individuals in our study of 31 healthcare workers were shown to have detectable PARV4 DNA by the method described herein (Chen MY, unpublished data). The hypothesis is also in agreement with the high PARV4 DNA-positive rates observed in Ghanaian infants.
and children [21]. To address this issue, prospective studies on PARV4 infection in pregnant women and their newborns in PARV4 endemic areas are required.

Competing interests
The authors declare no competing interest regarding the present study.

Authors’ contributions
CM performed laboratory tests and prepared the manuscript, HC and LG participated in the sample collection and data analysis. All authors have read and approved the final manuscript.

Authors’ information
CM and LK are medical doctors at the Department of Internal Medicine, National Taiwan University Hospital (NTUH) in Taipei, Taiwan. HC works at the AIDS Center in NTUH and is an infectious disease specialist at NTUH.

Acknowledgement
We are grateful to the participants of this study.

Received: 1 December 2014 Accepted: 16 June 2015
Published online: 19 June 2015

References
1. Brown KE. The expanding range of parvoviruses which infect humans. Rev Med Virol. 2010;20:231–44.
2. Jones MS, Kapoor A, Lukashov VV, Simmonds P, Hecht F, Delwart E. New DNA viruses identified in patients with acute viral infection syndrome. J Virol. 2005;79:8230–6.
3. Sharp CP, Vermeulen M, Nébié Y, Djoko CF, LeBreton M, Tamoufe U, et al. Epidemiology of human parvovirus 4 infection in Sub-Saharan Africa. Emerg Infect Dis. 2010;16:1605–7.
4. Sharp CP, Lair A, Donfield S, Simmons R, Leen C, Klennerman P, et al. High frequencies of exposure to the novel human parvovirus PARV4 in hemophiliacs and injection drug users. J Infect Dis. 2009;200:1119–25.
5. Lahtinen A, Kivelä P, Hedman L, Kumar A, Kantele A, Lappalainen M, et al. Serodiagnosis of primary infections with human parvovirus 4 Finland. Emerg Infect Dis. 2011;17:79–82.
6. Tamoličius PL, Simutis K, Kudži M, Frantienė R, Emuštyte R, Petrylaitytė–Burnelkienė R, et al. Production of human parvovirus 4 VP2 virus-like particles in yeast and their evaluation as an antigen for detection of virus-specific antibodies in human serum. Intervirology. 2013;56:271–7.
7. Maple PAC, Beard S, Pany RP, Brown KE. Testing UK blood donors for exposure to human parvovirus 4 using a time-resolved fluorescence immunoassay to screen sera and western blot to confirm reactive samples. Transfusion. 2013;53:2575–84.
8. Lefrère JJ. Servant-Delmas A, Candotti D, Mariotti M, Thomas I, Brossard Y, et al. Persistent B19 infection in immunocompetent individuals: implications for transfusion safety. Blood. 2005;106:2680–5.
9. Norja P, Hokynar K, Aaltonen LM, Chen R, Ranki A, Partio EK, et al. Bioportfolio: lifelong persistence of variant and prototypic erythrovirus DNA genomes in human tissue. Proc Natl Acad Sci USA. 2006;103:7450–3.
10. Simmons R, Sharp C, Levine J, Bowness P, Simmonds P, Cox A, et al. Evolution of CD8+ T cell responses after acute PARV4 infection. J Virol. 2013;87:3087–96.
11. Schneider B, Fyer JF, Reber U, Fischer HP, Tolba RH, Baylis SA, et al. Persistence of novel human parvovirus PARV4 in liver tissue of adults. J Med Virol. 2008;80:345–51.
12. Corcoci F, Zakrzewska K, Fanci R, De Giorgi V, Innocenti M, Rotelli M, et al. Human parvovirus PARV4 DNA in tissues from adult individuals: a comparison with human parvovirus B19 (B19V). Virol J. 2010;7:227–6.
13. Manning A, Willey SJ, Bell JE, Simmonds P. Comparison of tissue distribution, persistence and molecular epidemiology of parvovirus B19 and novel human parvoviruses PARV4 and human bocavirus. J Infect Dis. 2007;195:1345–52.
14. Candotti D, Elz N, Parsyan A, Allain JP. Identification and characterization of persistent human erythrovirus infection in blood donor samples. J Virol. 2004;22:12169–78.
15. Fryer JF, Delwart E, Hecht FM, Bernardin F, Jones MS, Shah N, et al. Frequent detection of the parvoviruses, PAR4 and PARVs, in plasma from blood donors and symptomatic individuals. Transfusion. 2007;47:1054–61.
16. Simmons R, Sharp C, Sims S, Kloverpris H, Goulder P, Simmonds P, et al. High frequency, sustained T cell responses to PARV4 suggest viral persistence in vivo. J Clin Virol. 2011;51:647–7.
17. Yang SJ, Hung CC, Chang SY, Lee KL, Chen MY. Immunoglobulin G and M antibodies to human Parvovirus 4 (PARV4) are frequently detected in patients with HIV-1 Infection. J Clin Virol. 2011;51:647–7.
18. Lou S, Xu B, Huang Q, Zhi N, Cheng F, Wong S, et al. Molecular characterization of the newly identified human parvovirus 4 in the family parvoviridae. Virol. 2012;423:59–69.
19. Söderlund M, Brown CS, Spana WM, Hedman L, Hedman K. Epitope type-specific IgG response to capsid proteins VP1 and VP2 of human parvovirus B19. J Infect Dis. 1995;127:1431–6.
20. Chen MY, Yang SJ, Hung CC. Placental transmission of human parvovirus 4 in newborns with hydrops, Taiwan. Emerg Infect Dis. 2011;17:1954–6.
21. Panning M, Kobbé R, Volbach S, Drexler JF, Adjei J, Adjei O, et al. Novel human parvovirus 4 genotype 3 in infants, Ghana. Emerg Infect Dis. 2010;16:1143–6.

Submit your next manuscript to BioMed Central and take full advantage of:
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit